Here we report that tirzepatide (TZP), a novel polypeptide/glucagon‐like peptide 1 receptor (GIPR/GLP‐1R) agonist for the treatment of diabetes, has a role in attenuating CRC growth. This evidence concerns the gene GLP1R and colorectal carcinoma.